SavedAdd your journal

Journals / Archives of health science and research (Online) / 2020 / Cilt: 7 - Sayı: 2

Occupational Exposure to Antineoplastic Drugs and Nursing

Antineoplastik İlaçlara Mesleki Maruziyet ve Hemşirelik

Sevcan TOPÇU
Ayşe BEŞER
Pages
207–212
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, the aim of this review is to evaluate the occupational exposure of nurses working with antineoplastic drugs and the preventive measures.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Health workers are exposed to antineoplastic drugs when working in the preparation and management of antineoplastic drugs or in the place where these drugs are used.
📊
Key Findings & Data:The development of oncology as a field of expertise in medicine, the increase of chemotherapy doses and combinations given to cancer patients, and the development of a supportive care area to help minimize or protect from the side effects of chemotherapy increase the occupational exposure of nurses to antineoplastic drugs.
💡
Conclusion & Impact:Therefore, the aim of this review is to evaluate the occupational exposure of nurses working with antineoplastic drugs and the preventive measures.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Health workers are exposed to antineoplastic drugs when working in the preparation and management of antineoplastic drugs or in the place where these drugs are used. The development of oncology as a field of expertise in medicine, the increase of chemotherapy doses and combinations given to cancer patients, and the development of a supportive care area to help minimize or protect from the side effects of chemotherapy increase the occupational exposure of nurses to antineoplastic drugs. Occupational exposure to antineoplastic drugs has many side effects and health problems in healthcare workers. This exposure may cause acute side effects such as skin rash, nausea, vomiting, diarrhea, constipation, alopecia, nail hyperpigmentation, dysuria, and insomnia, or chronic side effects such as infertility, miscarriage, damage to the fetus and embryo, leukemia, and breast cancer. Therefore, the aim of this review is to evaluate the occupational exposure of nurses working with antineoplastic drugs and the preventive measures.

Özet

Sağlık çalışanları antineoplastik ilaçların hazırlanması ve yönetimini gerçekleştirirken veya bu ilaçların kullanıldığı alanlarda çalışırken bu ilaçlara maruz kalmaktadır. Tıpta uzmanlık alanı olarak onkolojinin gelişmesi, kanser hastalarına verilen kemoterapi doz ve kombinasyonlarının artması, kemoterapinin yan etkilerini minimuma indirmek ve korumaya yardımcı olmak için destekleyici bakım alanının gelişmesi hemşirelerin antineoplastik ilaçlara olan maruziyetini arttırmaktadır. Antineoplastik ilaçlara mesleki maruziyetin sağlık çalışanlarında yarattığı birçok yan etki ve sağlık sorunu bulunmaktadır. Antineoplastik ilaçlara mesleki maruziyet, cilt döküntüsü, bulantı, kusma, diyare, konstipasyon, alopesi, tırnaklarda hiperpigmentasyon, dizüri, uykusuzluk gibi akut yan etkilere, infertilite, abortus, fetüs ve embriyoda hasar, lösemi ve meme kanseri gibi kronik yan etkilere neden olmaktadır. Bu nedenle bu derleme çalışmasının amacı antineoplastik ilaçlar ile çalışan hemşirelerin mesleki maruziyetlerinin ve korunma önlemlerinin değerlendirilmesidir.

🔖

Cite This Article

TOPÇU, S., BEŞER, A. (2022). Occupational Exposure to Antineoplastic Drugs and Nursing. Archives of health science and research (Online), Cilt: 7 - Sayı: 2, 207–212. https://ajindex.com/articles/447923

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. WHO. Occupational Health: Health Worker Occupational Health. Available from: https://www.who.int/occupational_health/topics/ hcworkers/en/
  2. Occupational Safety and Health Administration (OSHA). Healthcare. Available from: https://www.osha.gov/SLTC/healthcarefacilities /index.html
  3. ASHP. ASHP Technical Assistance Bulletin on Handling Cytotoxic and Hazardous Drugs. Am J Hosp Pharm 1990; 47: 1033-49
  4. The National Institute for Occupational Safety and Health (NIOSH). Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. 2004. Availabe from:
  5. Connor TH, MacKenzie BA, DeBord DG, Trout DB, O'Callaghan JP. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. Cincinnati, Ohio: US. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupa¬tional Safety and Health, DHHS (NIOSH).
  6. Polovich M. Minimizing Occupational Exposure to Antineoplastic Agents. J Infus Nurs 2016; 39: 307-13
  7. Wang X, Zhang H, Chen X. Drug resistance and Combating Drug Resistance in Cancer. Canc Drug Resist 2019; 2: 141-60
  8. Al-Azzam SI, Awawdeh BT, Alzoubi KH, Khader YS, Alkafajei AM. Compliance With Safe Handling Guidelines of Antineoplastic Drugs in Jordanian Hospitals. J Oncol Pharm Pract 2015; 21: 3-9
  9. Amadori D, Ronconi S. Secondary lung tumors in hematological patients. Semin Respir Crit Care Med 2005; 26: 520-6
  10. Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, et al. Secondary Acute Myelogenous Leukemia in Patients with Retinoblastoma: ıs Chemotherapy A Factor? Ophthalmology 2007; 114: 1378-83
  11. Sugiura SI, Asano M, Kinoshita K, Tanimura M, Nabeshima T. Risks to Health Professionals from Hazardous Drugs in Japan: A Pilot Study of Environmental and Biological Monitoring of Occupational Exposure to Cyclophosphamide. J Oncol Pharm Pract 2011; 17: 14-9
  12. Onkoloji Hemşireliği Derneği. Antineoplastik İlaçların Güvenli Kullanım Standartları Rehberi. 2009. Available from:
  13. Nixon S,Schulmeister L. Safe handling of Hazardous Drugs: Are You Protected? Clin J Oncol Nurs 2009; 13: 433-9
  14. Eisenberg S. Safe handling and Administration of Antineoplastic Chemotherapy. J Infus Nurs 2009; 32: 23-32
  15. Celano P, Fausel CA,